Combination oral antiangiogenic therapy with thalidomide and sulindac inhibits tumour growth in rabbits
1999
Combining Thalidomide and Sulindac to Fight Tumors
publication
Evidence: moderate
Author Information
Author(s): Verheul H M W, Panigrahy D, Yuan J, D'Amato R J
Primary Institution: Children's Hospital, Harvard Medical School
Hypothesis
Can the combination of thalidomide and sulindac effectively inhibit tumor growth?
Conclusion
The combination of thalidomide and sulindac significantly inhibits tumor growth in rabbits.
Supporting Evidence
- Sulindac inhibited bFGF-induced neovascularization by 50% and VEGF-induced neovascularization by 55%.
- Thalidomide inhibited growth factor-induced corneal neovascularization.
- The combination of sulindac and thalidomide inhibited bFGF- or VEGF-induced corneal neovascularization by 63% or 74% respectively.
- Oral treatment of thalidomide or sulindac alone inhibited tumor growth by 55% and 35% respectively.
- The combination inhibited the growth of V2 carcinoma by 75%.
Takeaway
This study found that using two medicines together can help stop tumors from growing better than using them alone.
Methodology
The study tested the effects of thalidomide and sulindac on tumor growth in rabbits.
Participant Demographics
Rabbits were used as the model for testing.
Statistical Information
P-Value
p<0.01
Statistical Significance
p<0.01
Digital Object Identifier (DOI)
Want to read the original?
Access the complete publication on the publisher's website